Revenue segments as reported by the company.

Product, net

Revenue from anti-CD20 therapeutic programs

Other

Revenue from LEQEMBI Collaboration

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Selling, general and administrative

Amortization and impairment of acquired intangible assets

Collaboration profit sharing

(Gain) loss on divestiture of Hillerød, Denmark manufacturing operations

(Gain) loss on fair value remeasurement of contingent consideration

Acquired in-process research and development

Restructuring charges

Other (income) expense, net

Gain on sale of building

Gain on sale of PRV

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Biogen

Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. It offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for the treatment of multiple sclerosis, SPINRAZA for the treatment of spinal muscular atrophy, and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Biogen reports Q4 results, focuses on cost-saving and growth strategies

Biogen's Q4 2022 performance showed a revenue decline but an increase in non-GAAP diluted EPS.
The company is prioritizing cost-saving initiatives and strategic product launches for growth.
Challenges include managing expenses, evaluating R&D programs, and balancing cost reductions with investments.
Opportunities lie in upcoming product launches, potential acquisitions, and expanding into new therapeutic areas.

Biogen reports $2.5B revenue in Q1 2023, focuses on transformative drug launches

Biogen's Q1 2023 performance showed revenue stability despite challenges in MS product revenue.
The company's strengths lie in its focus on transformative drug launches and Alzheimer's research advancements.
Challenges include reimbursement expectations and managing the transition period until 2025.
Opportunities exist in external growth strategies, asset prioritization, and commercial launches for LEQEMBI and Zuranolone.

Biogen reports mixed Q2 earnings, LEQEMBI approval drives optimism

Biogen's Q2 2023 Earnings Call showcased mixed financial performance, with a focus on cost-saving initiatives and pipeline advancements. LEQEMBI's approval and positioning as a maintenance treatment offer promise, while challenges in revenue decline and market adoption persist. Strategic initiatives and upcoming milestones provide opportunities for growth and portfolio enhancement.

Biogen reports solid Q3 earnings, eyes regulatory approvals and market expansion

Biogen's Q3 2023 performance reflects steady growth, strategic initiatives, and promising product developments.
Strengths in sustainable growth priorities, product launches, and cost optimization position Biogen for long-term success.
Challenges in market expansion and operational efficiency require focused efforts on infrastructure and process improvements.
Opportunities in regulatory approvals, market expansion, and therapeutic advancements pave the way for future growth and innovation.

Biogen reports Q4 revenue decline but eyes growth opportunities

Biogen's Q4 2023 performance saw revenue decline offset by growth in rare disease revenue.
The company's strategic strengths lie in new product launches, cost reduction initiatives, and a focused pipeline strategy.
Challenges include bottlenecks in product launches and trial size reductions, while opportunities exist in upcoming milestones and market expansion.
Overall, Biogen aims for sustainable growth with a diversified product portfolio and strategic market focus.

Biogen reports robust Q1 earnings, focuses on market expansion

Biogen's Q1 performance reflects strong earnings growth and strategic focus on new launches. Despite challenges in launch processes, the company is capitalizing on market penetration opportunities. With a robust balance sheet and ongoing market expansion efforts, Biogen is poised for continued growth and success.

Biogen reports robust Q2 earnings, eyes growth in new launches

Biogen's Q2 2024 earnings call highlighted strong financial performance, successful product launches, and strategic priorities for growth. While challenges in the MS franchise persist, the company remains focused on sustainable growth through R&D investments and acquisitions. Opportunities for growth exist in expanding product portfolios and upcoming data releases.

Biogen reports mixed Q3 results, focuses on growth strategies

Biogen's Q3 2024 performance was mixed, with revenue growth in key products but overall revenue decline.
The company faces challenges in certain product segments but shows strength in new product development.
Opportunities lie in expanding market presence, new product launches, and potential business development.
Despite profitability challenges, Biogen's focus on growth strategies positions it for future success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.

Biogen has been a market-beating stock this year, but can that trend continue?

Is Biogen Poised for a Bull Run?

Acumen Pharmaceuticals

Athira Pharma

Anavex Life Sciences

BioVie Inc

Eli Lilly

Prothena

Roche Holding AG

Cassava Sciences Inc

The Clinical Trials on Alzheimer's Conference will take place from November 29, 2022 to December 2, 2022. Representatives of several listed companies will present data, including Eisai, Anavex, BioVie, Athira Pharma, Cassava Sciences and NervGen.

Trading Ideas On The Upcoming CTAD 2022 Conference

Biogen appears set to obtain approval of a 2nd Alzheimer's drug. Lecanemab is far better received by the market with total peak sales forecasted at up to $14 billion with Biogen sharing 50% of the profits.

Biogen: Second Time's A Charm

AbbVie

Alnylam Pharmaceuticals

Amgen

Karuna Therapeutics Inc

Pfizer

Zai Lab Ltd.

Recent clinical successes and M&A could bring interest back to biotechnology, especially among mid-capitalization names with derisked or approved products. Restructuring, corporate activity, and COVID-19 revenues have significantly improved the funding positions of many large biopharma companies, providing ample dry powder for M&A.

Deal Activity Could Jumpstart Biotechnology

Biogen remains a financially cheap, unloved Big Pharma name with a number of promising drugs under development. The latest positive readout on LECANEMAB, its second Alzheimer's drug likely to get FDA approval, could increase EPS dramatically in future years.

Biogen: Super-Strong Momentum In A Defensive Sector

LONDON--(BUSINESS WIRE)---- $BIIB #CDKL5--The Loulou Foundation, a private foundation dedicated to the development of therapeutics for the neurodevelopmental condition CDKL5 Deficiency Disorder (CDD), announced today that the first patient has been enrolled in the three-year observational study with CDD patients, the Clinical Assessment of NeuroDevelopmental measures In CDD (CANDID) study.

Loulou Foundation announces First-Patient-In for CANDID observational study on CDKL5 Deficiency Disorder

Albemarle

Constellation Energy Corp

Dollar General

Enphase Energy

Halliburton

Nielsen Hlds

SolarEdge Technologies

Twitter

Investors finally got a decent month in the S&P 500. And some really maximized their gains.

10 Stocks Turned $10,000 To $190,479 In 10 Months

CAMBRIDGE, Mass., Oct. 26, 2022 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) announced new data on multiple sclerosis (MS) disease measurement and advanced analytics being presented at the 38th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) meeting October 26-28, 2022. These data highlight Biogen's multi-pronged approach to pursue MS-related digital health research aimed at supporting the development of new treatments, individualizing care, and advancing the understanding of disease heterogeneity.

Biogen Data at ECTRIMS 2022 Highlight Innovation in Digital Health Focused on Advancing Treatment and Personalized Care of People Living with MS

CAMBRIDGE, Mass., Oct. 26, 2022 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) announced new data from its industry-leading portfolio of multiple sclerosis (MS) therapies being presented at the 38th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) meeting October 26-28, 2022. The presentations include the final safety and efficacy results of the VUMERITY® (diroximel fumarate) EVOLVE-MS-1 study, as well as a matching analysis comparing treatment with VUMERITY to Ponvory® (ponesimod) and Aubagio® (teriflunomide); patient-reported outcomes and an analysis of the proprietary StratifyJCV™ assay for TYSABRI® (natalizumab); a study evaluating treatment with TECFIDERA® (dimethyl fumarate) to prevent first clinical manifestation of MS for people with radiologically isolated syndrome; and studies assessing the impact of PLEGRIDY® (peginterferon beta-1a) and AVONEX® (interferon beta-1a) on pregnancy, breastfeeding and child development.

New Data at ECTRIMS 2022 Highlight Biogen's Commitment to Advancing Individualized Disease Management for People Living with MS

There's a much bigger story for this biotech than its improved 2022 outlook.

Is Biogen a Buy After It Boosted Guidance?

The biotech raised its earnings per share estimate to $16.50 to $17.15 from the previously estimated $15.25 to $16.75 range.

Biogen Lifts Profit Estimates as Investors Look to Alzheimer's Drug

Biogen (BIIB) beats third-quarter estimates for earnings and sales. Stock rises in pre-market as management raises the company's full-year 2022 financial guidance.

Biogen (BIIB) Beats on Q3 Earnings & Sales, Raises 2022 Outlook

Biogen Inc. BIIB, -2.03% and Eisai Co. Ltd. 4523, +3.57% are getting closer to possible approval of their new treatment for Alzheimer's disease, with plans to submit the drug for full Food and Drug Administration approval by March of next year.

Biogen and Eisai make plans to take another Alzheimer's drug to the FDA

Biogen Inc. (NASDAQ:BIIB ) Q3 2022 Earnings Conference Call October 25, 2022 8:00 AM ET Company Participants Mike Hencke - Head, Investor Relations Michel Vounatsos - Chief Executive Officer Priya Singhal - Interim Head, Research & Development Michael McDonnell - Chief Financial Officer Conference Call Participants Umer Raffat - Evercore Brian Abrahams - RBC Capital Markets Salveen Richter - Goldman Sachs Tim Anderson - Wolfe Research Chris Raymond - Piper Sandler Matthew Harrison - Morgan Stanley Brian Skorney - Baird Michael Yee - Jefferies Robyn Karnauskas - Truist Securities Jay Olson - Oppenheimer Phil Nadeau - Cowen and Company Marc Goodman - SVB Securities Chris Schott - JPMorgan Paul Matteis - Stifel Geoff Meacham - Bank of America Operator Good morning. My name is Jennifer, and I will be your conference operator today.

Biogen Inc. (BIIB) Q3 2022 Earnings Call Transcript

Biogen Inc. (BIIB) delivered earnings and revenue surprises of 15.50% and 1.60%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Biogen Inc. (BIIB) Surpasses Q3 Earnings and Revenue Estimates

Biogen stock rose Tuesday after the company beat views and raised guidance. The next big catalyst?

Biogen Inches Higher On Third-Quarter Beat, But All Eyes Watch Alzheimer's Drug

Biogen raised its earnings per share estimate to $16.50 to $17.15, up from the previously estimated $15.25 to $16.75 range.

Biogen Lifts Profit Estimates. The Stock Rises.

Biogen's BIIB, +2.62% stock was up 0.7% in premarket trading on Tuesday after it beat expectations for earnings and revenue in the third quarter of the year. The company had earnings of $1.1 billion, or $7.84 per share, in the third quarter of 2022, compared with $2.5 billion, or $2.22 per share, in the same quarter a year ago.

Biogen beats revenue expectations in the third quarter

Biogen's (BIIB) sales in the third quarter are likely to have been hurt by lower sales of Tecfidera and Spinraza.

Biogen (BIIB) to Report Q3 Earnings: Here's What to Expect

AstraZeneca

Alzheimer's treatments could make a big winner of these stocks.

3 Alzheimer's Therapy Stocks to Invest in

Is this biotech an investment worth buying and holding today?

Where Will Biogen Be in 5 Years?

The FDA extends the review period for Biogen's (BIIB) NDA for tofersen in SOD1-ALS. This extension is due to BIIB's submission of additional data, constituting a major amendment to the earlier filing.

Biogen's (BIIB) FDA Filing for ALS Drug Gets 3 Months Extension

A Roche executive said on Tuesday that positive trial data on an Alzheimer's disease drug candidate by rival Biogen was encouraging for companies such as Roche also pursing amyloid beta proteins as a drug target.

Roche exec says Biogen Alzheimer's data was reassuring

Biogen is positioned to become more diversified over time. A diminishing risk profile combined with emerging growth prospects make the stock attractive.

Biogen's Stock Pullback Offers a Second Chance

Lecanemab's successful Phase 3 clinical trial led to Biogen's stock price jumping by 33% in one day. From the reaction to Aduhelm's approval and option chain data, we see that the current stock price reflects a split likelihood on lecanemab's approval.

News for Biogen Stock (BIIB)